高强度间歇训练对喘患者吸入皮质类固醇剂量的影响:一项随机对照试验
Anders Pitzner-Fabricius1, Christian H Dall2, Marius Henriksen3
1Centre for Physical Activity Research, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark; The Parker Institute, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
概括
监督运动训练显著减少了喘患者的吸入性皮质类固醇 (ICS) 剂量. 这种高强度间歇训练计划降低了24%的日常ICS要求,而没有恶化喘控制.
科学领域:
- 肺部病理学 肺部病理学
- 运动生理学 运动生理学
- 临床医学 临床医学
背景情况:
- 吸入性皮质类固醇 (ICS) 是主要的喘治疗方法,但具有副作用,需要降低剂量.
- 众所周知,体育炼可以改善喘控制,但其对减少ICS依赖性的影响尚不清楚.
研究的目的:
- 调查是否有监督的高强度间歇训练 (HIIT) 可以降低患有喘但不习惯运动的成年人对ICS的需求.
主要方法:
- 一个为期6个月的单中心随机对照试验,涉及150名未经训练的成年人,在ICS上有症状喘.
- 参与者被随机分配到每周三次监督HIIT或通常的生活方式.
- 根据使用临床算法对症状控制进行每两个月一次的ICS剂量调整.
主要成果:
- 运动组的平均每日ICS剂量减少为234μg (与基线相比24%),明显高于对照组 (P = .0037).
- 虽然运动组中的63%的人实现了≥25%的ICS剂量减少,而对照组的50%是如此,但这并没有达到统计学意义 (P = .15).
- 降低ICS剂量维持在12个月,运动干预被发现是安全的和耐受良好.
结论:
- 六个月的定期,监督的运动有效地减少了喘患者每日吸入的皮质类固醇剂量.
- 这种运动干预可以实现ICS剂量降低,而不会对喘症状控制产生负面影响.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
319
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
319
COPD: Management Using Bronchodilators and Corticosteroids
256
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
256
Inhaled Medications
323
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
323
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Antiasthma Drugs: β2-Adrenoceptor Agonists
319
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
319
Antiasthma Drugs: Leukotriene Modifiers
379
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
379


